靶向CD40的鼻内重组MERS-CoV S1蛋白疫苗在小鼠中诱发的全身和黏膜免疫应答优于肌内免疫
本研究开发了靶向CD40表达抗原提呈细胞的MERS-CoV S1亚单位自佐剂融合蛋白疫苗(S1-F/CD40L),在小鼠中比较了铝佐剂与CpG佐剂联合、肌内与鼻内免疫途径的免疫原性。结果显示,鼻内接种S1-F/CD40L可诱导与肌内接种相当的全身体液和细胞免疫,且肺部局部黏膜免疫和循环IgA水平显著高于肌内接种。
要点
- S1-F/CD40L联合铝佐剂和CpG的肌内注射在全身抗原特异性体液和细胞应答及Th1优势表型方面优于单用铝佐剂或CpG。
- 两剂肌内或鼻内S1-F/CD40L和S1均具免疫原性,可诱导小鼠产生IgG、IgA、中和抗体和T细胞应答,CD40靶向S1组应答更强。
- 鼻内S1-F/CD40L诱导的全身免疫与肌内接种相当,但肺部黏膜免疫和循环IgA水平显著高于肌内接种。
核心结论
- S1-F/CD40L联合铝佐剂和CpG可作为针对MERS-CoV的有效且安全的黏膜候选疫苗。
- 将CD40L作为抗原提呈细胞靶向配体和分子佐剂可增强免疫原性,为应对未来新发病原体和可能的暴发提供有前景的平台。
研究设计与样本
- 研究为小鼠免疫原性实验,开发了靶向CD40表达抗原提呈细胞的MERS-CoV S1亚单位自佐剂融合蛋白疫苗(S1-F/CD40L)。
- 比较了S1-F/CD40L联合铝佐剂和CpG与单用铝佐剂或CpG的肌内注射效果。
- 比较了S1-F/CD40L与S1通过肌内和鼻内两种途径接种的免疫原性。
主要发现
- 肌内注射S1-F/CD40L联合铝佐剂和CpG在全身抗原特异性体液和细胞应答及Th1优势表型方面优于单用铝佐剂或CpG。
- 两剂肌内或鼻内S1-F/CD40L和S1均具免疫原性,可诱导小鼠产生IgG、IgA、中和抗体和T细胞应答,CD40靶向S1组应答更强。
- 鼻内接种S1-F/CD40L诱导的全身体液和细胞免疫应答与肌内接种相当,包括结合抗体、中和抗体和T细胞应答。
- 鼻内疫苗在小鼠肺部诱导的局部黏膜体液和细胞免疫应答显著高于肌内接种,循环IgA水平也显著升高。
临床怎么用
- 作者认为,S1-F/CD40L联合铝佐剂和CpG可作为针对MERS-CoV的有效且安全的黏膜候选疫苗。
- 作者认为,将CD40L作为抗原提呈细胞靶向配体和分子佐剂可增强免疫原性,为应对未来新发病原体和可能的暴发提供有前景的平台。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Middle East respiratory syndrome coronavirus (MERS-CoV) is a global One Health challenge with a potential pandemic threat, with no approved vaccines or antiviral drugs available to date. Thus, there is an urgent need for a safe and effective vaccine. Herein, we developed a recombinant subunit self-adjuvanted fusion protein vaccine targeting the MERS-CoV S1 subunit to CD40-expessing APCs (S1-F/CD40L). We found that intramuscular injection of S1-F/CD40L in conjunction with Alum and CpG was superior to Alum or CpG alone in terms of systemic Ag-specific humoral and cellular responses and Th1-dominant phenotype. Furthermore, the immunogenicity of co-adjuvanted S1-F/CD40L was compared to that of S1 alone via both intramuscular and intranasal immunization. Two intramuscular and intranasal doses of S1-F/CD40L and S1 were immunogenic in eliciting systemic and mucosal humoral and cellular immunity, including IgG, IgA, neutralizing antibodies (nAbs), and T cell responses in mice, with a greater response in the CD40-targeted S1 group. Intranasal vaccination with S1-F/CD40L induced systemic humoral and cellular immune responses comparable to those induced by intramuscular vaccination, including binding and nAbs and T cell responses. Importantly, intranasal vaccine was able to elicit significantly higher local mucosal humoral and cellular immune responses in mouse lungs and markedly elevated circulating IgA levels compared to intramuscular vaccination. Collectively, our results suggest that the S1-F/CD40L vaccine co-adjuvanted with Alum and CpG can be used as an effective and safe mucosal candidate vaccine against MERS-CoV. Furthermore, these data demonstrate that the incorporation of CD40L as APCs targeting ligand and molecular adjuvant enhances immunogenicity, thus offering a promising platform that could be explored further to respond to future emerging pathogens and possible outbreaks.
引用
- Khan MY, Aljehani ND, Abdulal RH, et al. Intranasal CD40-targeted recombinant MERS-CoV S1 protein is superior to intramuscular immunization in eliciting systemic and mucosal immune responses in mice. Vaccine. 2025. PMID: 41232171. doi:10.1016/j.vaccine.2025.127975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。